Vialwirebiotech, curated
November 21, 2026, 6:18 AM
November 6, 2026
- 10:35 PM · SCMP — Tech10:35 PMUS regulator investigates tumour risk in children given Novartis gene therapy — SCMP — Tech
- 4:52 PM · NYT — Health4:52 PMBiotech Firm Claims Some Credit for Groundbreaking Virus Research — NYT — Health
- 11:47 AM · FT — Pharmaceuticals11:47 AM‘De-extinction’ start-up Colossal accuses ex-staffer of stealing secrets — FT — Pharmaceuticals
- 11:00 AM · BioWorld11:00 AMQyuns lands $780M Caldera deal, expands bispecific partnership — BioWorld
- 11:00 AM · BioWorld11:00 AMUK commercial clinical trial recruitment falls 5th year in a row — BioWorld
- 11:00 AM · BioWorld11:00 AMSeven biopharma IPOs in October lift 2026 total to nearly $10B — BioWorld
- 10:11 AM · Pharmaceutical Executive10:11 AM<![CDATA[Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines ]]> — Pharmaceutical Executive
- 9:35 AM · Pharmaceutical Executive9:35 AM<![CDATA[Novo Terminates Research Collaboration With Korro Bio ]]> — Pharmaceutical Executive
- 9:16 AM · Drug Discovery World9:16 AMAnaheim Bio launches with €40 million Series A financing — Drug Discovery World
- 8:00 AM · BioWorld8:00 AMKayak Therapeutics gains IND clearance for TRIM7 inhibitor — BioWorld
- 8:00 AM · BioWorld8:00 AMSaniona eyes CTA submission for SAN-2668 — BioWorld
- 6:43 AM · Drug Discovery World6:43 AMResolution to present positive interim data for regenerative macrophage therapy — Drug Discovery World
- 6:34 AM · Pharmaceutical Technology6:34 AMFDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval — Pharmaceutical Technology
- 5:41 AM · Pharmaceutical Technology5:41 AMArmada to combine with Brains Bioceutical in $750m deal — Pharmaceutical Technology
- 4:57 AM · Pharmaceutical Technology4:57 AMAlfasigma receives EC’s expanded approval for filgotinib to treat axSpA — Pharmaceutical Technology
November 5, 2026
- 9:00 PM · Science (News)9:00 PMCalifornians poised to approve controversial $8.4 billion initiative to fund immunology research — Science (News)
- 4:06 PM · BioPharma Dive4:06 PMMedicare will cut billions from 340B, expand site-neutral payments in 2027 — BioPharma Dive
- 12:09 PM · BioPharma Dive12:09 PMAt ASH, drugmakers to showcase early data for three-pronged cancer therapies — BioPharma Dive
- 11:22 AM · STAT News11:22 AMSTAT+: A possible comeback for a failed sickle cell gene therapy — STAT News
- 11:10 AM · Pharmaceutical Technology11:10 AMCordavis to stay in CVS Health after bifurcation of $117bn empire — Pharmaceutical Technology
- 11:00 AM · BioWorld11:00 AMAni buying Egetis for newly approved rare disease drug Emcitate — BioWorld
- 11:00 AM · BioWorld11:00 AMCCR8, who do we appreciate? Multiple players busy — BioWorld
- 11:00 AM · BioWorld11:00 AMAska pays Minghui $110M up front for Japan TED rights — BioWorld
- 11:00 AM · BioWorld11:00 AMSiemens Healthineers to drop ‘Siemens’, starts diagnostics carve-out — BioWorld
- 8:00 AM · BioWorld8:00 AMBlueprint Medicines patents new CDK4-targeting PROTACs — BioWorld
- 8:00 AM · BioWorld8:00 AMSuzhou Puhe Biopharma synthesizes new MAT2A inhibitors — BioWorld
- 8:00 AM · BioWorld8:00 AMGENC-231 improves renal function in preclinical CKD — BioWorld
- 8:00 AM · BioWorld8:00 AMExegenesis Bio presents SMA gene therapy EXG-201 — BioWorld
- 8:00 AM · BioWorld8:00 AMHenlius’ IL1RAP-targeted antibody cleared for clinic — BioWorld
- 8:00 AM · BioWorld
- 8:00 AM · BioWorld8:00 AMSeagen identifies new TFRC-targeting antibody-drug conjugates — BioWorld
- 8:00 AM · BioWorld8:00 AMSepterna selects Graves’ disease candidate — BioWorld
- 8:00 AM · BioWorld8:00 AMLink Biologics completes IND-enabling program for LB-001 — BioWorld
- 8:00 AM · BioWorld
- 8:00 AM · BioWorld8:00 AMKimia collaborates with Cstone to advance KT-721 into clinic — BioWorld
- 8:00 AM · BioWorld
- 7:52 AM · BioPharma Dive7:52 AMT-Therapeutics reloads with a $133M megaround for bispecifics — BioPharma Dive
- 7:33 AM · STAT News7:33 AMSTAT+: Revolution’s pancreatic cancer drug has stunning commercial debut — STAT News
- 6:51 AM · Drug Discovery World6:51 AMUQ selected by US government to develop RNA medicines — Drug Discovery World
- 6:30 AM · STAT News6:30 AMSTAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug — STAT News